Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Hold” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given an average recommendation of “Hold” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and two have issued a strong buy rating on the company.

Several equities analysts recently commented on ZLDPF shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF remained flat at $44.86 on Friday. The company’s stock had a trading volume of 28 shares, compared to its average volume of 178. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The stock’s 50 day simple moving average is $46.95 and its two-hundred day simple moving average is $53.39. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12. The company has a market cap of $3.21 billion, a price-to-earnings ratio of 3.33 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The firm had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. Analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.